Go to JCI Insight
Jci spelled out white on transparent.20160208
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Cellular senescence in human disease (Apr 2018)
    • Fibrosis (Jan 2018)
    • Glia and Neurodegeneration (Sep 2017)
    • Transplantation (Jun 2017)
    • Nuclear Receptors (Apr 2017)
    • Metabolism and Inflammation (Jan 2017)
    • Hypoxia and Inflammation (Oct 2016)
    • View all review series...
  • Collections
    • Recently published
    • Commentaries
    • Concise Communication
    • Editorials
    • Opinion
    • Scientific Show Stoppers
    • Top read articles
    • In-Press Preview
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

Jci only white

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
Olfactory receptor 544 reduces adiposity by steering fuel preference toward fats
Chunyan Wu, … , Seung-Hoi Koo, Sung-Joon Lee
Chunyan Wu, … , Seung-Hoi Koo, Sung-Joon Lee
Published November 1, 2017
Citation Information: J Clin Invest. 2017;127(11):4118-4123. https://doi.org/10.1172/JCI89344.
View: Text | PDF
Categories: Brief Report Metabolism

Olfactory receptor 544 reduces adiposity by steering fuel preference toward fats

  • Text
  • PDF
Abstract

Olfactory receptors (ORs) are present in tissues outside the olfactory system; however, the function of these receptors remains relatively unknown. Here, we determined that olfactory receptor 544 (Olfr544) is highly expressed in the liver and adipose tissue of mice and regulates cellular energy metabolism and obesity. Azelaic acid (AzA), an Olfr544 ligand, specifically induced PKA-dependent lipolysis in adipocytes and promoted fatty acid oxidation (FAO) and ketogenesis in liver, thus shifting the fuel preference to fats. After 6 weeks of administration, mice fed a high-fat diet (HFD) exhibited a marked reduction in adiposity. AzA treatment induced expression of PPAR-α and genes required for FAO in the liver and induced the expression of PPAR-γ coactivator 1-α (Ppargc1a) and uncoupling protein-1 (Ucp1) genes in brown adipose tissue (BAT). Moreover, treatment with AzA increased insulin sensitivity and ketone body levels. This led to a reduction in the respiratory quotient and an increase in the FAO rate, as indicated by indirect calorimetry. AzA treatment had similar antiobesogenic effects in HFD-fed ob/ob mice. Importantly, AzA-associated metabolic changes were completely abrogated in HFD-fed Olfr544–/– mice. To our knowledge, this is the first report to show that Olfr544 orchestrates the metabolic interplay between the liver and adipose tissue, mobilizing stored fats from adipose tissue and shifting the fuel preference to fats in the liver and BAT.

Authors

Chunyan Wu, Su Hyeon Hwang, Yaoyao Jia, Joobong Choi, Yeon-Ji Kim, Dahee Choi, Duleepa Pathiraja, In-Geol Choi, Seung-Hoi Koo, Sung-Joon Lee

×

Figure 1

Olfr544 activation by AzA stimulates lipolysis in 3T3-L1 adipocytes.

Options: View larger image (or click on image) Download as PowerPoint
Olfr544 activation by AzA stimulates lipolysis in 3T3-L1 adipocytes.
(A)...
(A) AzA increases cAMP concentrations (n = 4), but not intracellular calcium (n = 8) or inositol phosphate (IP) levels (n = 4). HTRF ratio, homogeneous time-resolved fluorescence ratio (665 nm/620 nm); RFU, relative fluorescence units. (B) PKA activity (n = 4). Relative PKA activity was measured using absorbance at 450 nm and normalized to the protein concentration. (C) Immunoblot analysis of phosphorylated HSL (p-HSL), HSL, and the p-HSL/HSL ratio (n = 3). (D) Intracellular triglyceride (n = 3) and cholesterol (n = 4) concentrations and adiponectin secretion (n = 4). (E) Glycerol release (n = 4). FSK, forskolin (1 μM); AzA (50 μM); A-23187 (10 μM), a calcium-ionophore positive control. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, and ****P < 0.0001, by 1-way ANOVA followed by Tukey’s HSD test or Student’s t test for comparison of 2 or more groups.
Follow JCI: Facebook logo white Twitter logo v2 Rss icon
Copyright © 2018 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts